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Abnormal kidney function is common in the course of human
immunodeficiency virus (HIV) infection. Here, we performed
a cross-sectional analysis using 399 patients within the
Aquitaine cohort (a hospital-based cohort of HIV-1-infected
patients receiving routine clinical management) to estimate
the prevalence of proximal renal tubular dysfunction (PRTD)
associated with HIV infection. These patients did not differ
statistically by sociodemographics, median age, years since
HIV diagnosis, AIDS stage, or median CD4 cell count from
the entire 3080 patient cohort. Antiretroviral therapy was
received by 352 patients, with 256 given tenofovir (TDF);
325 had undetectable HIV plasma viral load, and 26 were
diagnosed with PRTD. In multivariate analysis, significant
independent associations were found between PRTD and age
(odds ratio (OR) 1.28 per 5-year increase), atazanavir (OR 1.28
per year of exposure), and TDF (OR 1.23 per year) treatment.
Among patients having received TDF-containing regimens
over a 5-year period, PRTD remained significantly associated
with TDF exposure when treatment was ongoing (OR 5.22)
or had been discontinued (OR 11.49). Thus, cumulative
exposure to TDF and/or atazanavir was associated with
an increased risk of PRTD, with concern about its reversibility
in patients with HIV.
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The use of highly active antiretroviral therapy (HAART) has
drastically improved the prognosis of patients infected with
human immunodeficiency virus (HIV).1 In this new era of
HIV care management, non-AIDS-related complications of
HIV infection have become increasingly important. Among
these, kidney diseases are relatively common2,3 and HIV has
been shown to be directly involved in renal damage.4
Recently, repetitive case reports of kidney abnormalities
involving proximal tubular function have been reported5–8
and have been found to be associated with bone mineral
density abnormalities and/or long-term nephrotoxic effects.
Premature osteoporosis due to persistent phosphate loss may
indeed be a worrisome complication.9,10 Clinical research on
tubular function is challenging because of the complexity of
kidney exploration. Few studies have assessed prospectively
the tubular function of HIV-infected patients,11,12 and
prevalence estimates in unselected cohorts are scarce. The
objectives of this study were to assess the prevalence and
potential determinants of proximal renal tubular dysfunction
(PRTD) in a large cohort of French HIV-1-infected patients.
RESULTS
Between April 2008 and December 2009, 402 patients were
enrolled consecutively in the present study. The patients
who were sampled did not differ statistically from the
3080 patients actively followed in the Aquitaine cohort
participating centers in 2008–2009 according to sociodemo-
graphic and HIV characteristics (gender, median age, HIV
transmission group, year since HIV diagnosis, AIDS stage,
hepatitis B and C virus serological status, CD4 cell count,
and plasma HIV RNA; data not shown). Three patients had
incomplete kidney evaluation and were excluded from the
analysis.
Patients’ characteristics
Out of the 399 eligible patients, 301 were men and the
median age was 47.4 years (interquartile range (IQR):
or ig ina l a r t i c l e http://www.kidney-international.org
& 2011 International Society of Nephrology
Received 10 November 2010; revised 21 February 2011; accepted 1
March 2011; published online 4 May 2011
Correspondence: Fre´de´ric-Antoine Dauchy, Services de Maladies Infec-
tieuses et Tropicales and COREVIH, Hoˆpital Pellegrin, CHU de Bordeaux,
Universite´ Bordeaux Segalen, F-33076 Bordeaux, France.
E-mail: frederic.dauchy@chu-bordeaux.fr
302 Kidney International (2011) 80, 302–309
42.5–54.0). Patients were predominantly of Caucasian origin
(94.0%). Median follow-up since HIV infection diagnosis was
14.1 years (IQR: 8.2–18.5); 91 patients (22.8%) had reached
the AIDS stage. Most patients had acquired HIV infection
through homosexual transmission (45.6%), followed by
heterosexual transmission (30.8%), and intravenous drug
use (13.0%). Plasma viral load was o40 copies/ml in 325
patients (81.4%). Median CD4 count was 483 cells/mm3
(IQR: 353–648), and median nadir CD4 count was
200 cells/mm3 (IQR: 88–304). Chronic active hepatitis C
(HCV RNA positive) was present in 59 patients (14.9%) and
chronic hepatitis B (HBV surface antigen positive) in 23
patients (5.8%). The median body mass index was 22.3 kg/m2
(IQR: 20.7–24.7); body mass index was o20 kg/m2 in
71 patients (18.3%) and 425 kg/m2 in 85 patients (22.0%).
Clinically defined lipodystrophy was diagnosed in 195
patients (48.9%). Daily alcohol consumption was reported
in 83 patients (23.2%) and smoking (41 cigarette per day) in
171 patients (48.0%). Diabetes mellitus was present in
24 patients (6.1%) and hypertension in 32 patients (8.1%).
None of the study subjects experienced organ transplantation
or was taking immunosuppressive drugs. A previous diag-
nosis of kidney disease was reported in the medical records of
40 patients (10.0%), which consisted mainly in a history of
kidney lithiasis (31 patients, 7.8%). At the time of the survey,
352 patients (88.2%) were treated with HAART. The median
cumulated duration on HAART was 89.2 months (IQR:
34.7–122.0), 114.1 months (IQR: 51.4–144.4) for nucleoside
and nucleotide reverse transcriptase inhibitors (NRTIs), 13.2
months (IQR: 0–45.2) for non-nucleoside reverse transcrip-
tase inhibitors, and 35.3 months (IQR: 2.2–92.7) for protease
inhibitors (PIs); 256 (64.2%) patients had been exposed to
tenofovir (TDF) and 219 patients (54.9%) were currently
treated with TDF-containing regimens. The median cumu-
lated duration of TDF prescription was 16.3 months (IQR:
0–39.7). Previous exposure to other antivirals was observed in
100 patients (25.1%), and these drugs were mainly acyclovir
or ganciclovir. None of the patients had previously received
adefovir, and only three patients had previously prescribed
cidofovir. Previous exposure to cotrimoxazole was reported
in 167 patients (41.8%). Main characteristics of patients are
reported in Tables 1 and 2, according to absence or presence
of PRTD.
Kidney and tubular renal function
A detailed kidney function evaluation was performed on
urine and serum samples. Median glomerular filtration rate
(GFR) was 100.82ml/min per 1.73m2 (IQR: 84.63–115.89),
and median phosphatemia was 1.05mmol/l (IQR: 0.92–1.16).
Proteinuria was present in 46 (11.6%) patients and albumin-
uria in 128 (31.8%). According to the National Kidney
Foundation—Kidney Disease Outcomes Quality Initiative
Table 1 | Patients’ characteristics according to absence or presence of PRTD, Aquitaine cohort, 2008–2009 (n=399)
PRTD (n=26) No PRTD (n=373) P-value
Female gender (%) 19.2 24.9 0.51
Median age (years) 51.5 (46.8–59.1) 47.2 (42.2–53.4) 0.006
Median HIV infection duration (years) 10.2 (6.5–17.8) 14.2 (8.3–18.5) 0.30
Transmission risk group (%) 0.91
Homosexual 53.8 45.0
Intravenous drug use 7.7 13.4
Heterosexual 19.2 31.6
Other 19.2 9.9
AIDS clinical stage (%) 26.5 21.2 0.50
Diabetes mellitus (%) 3.8 6.2 0.63
Daily alcohol consumption (%) 25 23.1 0.88
Smoking (ever; %) 37.5 46.1 0.82
Lipodystrophy (%) 69.2 47.4 0.04
HBV chronic hepatitis (%) 11.5 5.5 0.21
HCV chronic hepatitis (%) 19.2 14.6 0.52
BMI (kg/m2; %) 0.83
o20 15.4 18.6
425 19.2 22.2
CD4 cells count 4200/mm3 (%) 96.2 94.5 0.74
Nadir CD4 cells count (/mm3) 208 (95–305) 200 (88–303) 0.87
Viral load o40 cp/ml (%) 88.5 81.0 0.34
Arterial hypertension (%) 11.5 7.8 0.51
Other antiviral drugsa (ever; %) 11.5 26 0.11
NSAID (ever; %) 3.8 0.8 0.13
Cotrimoxazole exposure (ever; %) 34.6 42.4 0.44
Abbreviations: BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; NSAID, non-steroidal anti-
inflammatory drugs; PRTD, proximal renal tubular dysfunction.
aAcyclovir, ganciclovir, adefovir, and cidofovir.
Data are percentage or median (IQR).
Bold values signify P-valueo0.05.
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classification,13 stage 1 of kidney disease was diagnosed in
18.9% of patients, stage 2 in 10.7%, stage 3 in 5.0%, and stage
4 in 0.3%. None of the patients had reached stage 5 (GFR
o15ml/min per 1.73m2).
Tubular function tests showed a phosphate diabetes in
7.0% of patients (95% confidence interval (CI): 4.7–10.2%),
non-diabetic glucosuria in 7.0% (95% CI: 4.6–10.0%),
metabolic acidosis in 7.2% (95% CI: 4.8–10.4%), b2-
microglobulinuria in 16.7% (95% CI: 12.6–21.6%), and low
serum uric acid with an elevated fractional excretion of uric
acid in 8.7% (95% CI: 6.0–12.2%). Finally, PRTD was
diagnosed in 26 patients (prevalence: 6.5% and 95% CI:
4.2–9.5%).
Correlates of tubular dysfunction
The factors associated with the presence of PRTD in the
univariable analysis and which were included in the multi-
variable full model were as follows: age, non-steroidal anti-
inflammatory drugs and other antiviral drugs exposure,
chronic hepatitis B, lipodystrophy, and cumulated exposure
to abacavir, TDF, atazanavir, and ritonavir used as boosters.
In the final model, older age (odds ratio (OR)¼ 1.28
per 5-year increase, P¼ 0.017), atazanavir (OR¼ 1.28 per
cumulative year of exposure, P¼ 0.021), and TDF (OR¼
1.23 per cumulative year of exposure, P¼ 0.028) were signi-
ficantly associated with a PRTD diagnosis (Table 3).
We performed an additional analysis to assess PRTD
reversibility after interruption of the antiretroviral drugs,
event that had been found to be associated with the outcome
of a tubular dysfunction (Table 4). Among patients having
received TDF-containing regimens over a 5-year period,
PRTD remained significantly associated when TDF use was
either ongoing (OR¼ 5.22, P¼ 0.03) or had been discon-
tinued before the study (OR¼ 11.49, P¼ 0.02). Conversely,
PRTD association with atazanavir was not significant when
the use of this drug had been interrupted before inclusion or
had been used for o4 years.
DISCUSSION
This cross-sectional survey assessed the prevalence of PRTD
and investigated associated factors within a relatively large
sample of unselected patients who underwent systematic
laboratory measurements and after applying a standardized
methodology. The prevalence of PRTD was high (6.5%),
considering that this dysfunction is uncommon in the general
population. These results are in agreement with other recent
reports on HIV-infected patients.14
Many studies have been conducted to estimate the
frequency of kidney diseases among HIV-infected patients
but few of them have estimated GFR and proteinuria.15,16
A relevant achievement of our survey was the opportunity
to detect renal diseases early (stages 1 and 2 in 29.6% of
patients) and to diagnose more important damages (stages
3–5 in 5.3% of the patients). These results are in agreement
with the EuroSIDA Cohort Study of advanced-stage renal
insufficiency (GFR estimated with the simplified modifica-
tion of diet in renal disease (MDRD) formula o60ml/min
per 1.73m2), with an estimated prevalence of 4.7% regardless
of proteinuria.2 Szczech et al.17 found the presence of
proteinuria in 30% of patients of a smaller sample. Renal
disorders in the earlier stages seem indeed very frequent in
HIV-infected patients, including within our sample of
patients who had achieved durable viral suppression, thanks
to HAART. As these abnormalities are not systematically
explored during routine follow-up, more clinical research
such as this one is needed to better characterize these changes
and propose interventions.
Fanconi’s syndrome, first described by Lignac et al.18 in
1924 and better defined by Fanconi et al.19 in 1936, is charac-
terized by a generalized transport defect in the proximal
Table 2 | Antiretroviral treatments according to absence or
presence of PRTD, Aquitaine cohort, 2008–2009 (n=399)
PRTD (n=26) No PRTD (n=373) P-value
HAART regimensa 98.9 (57.1–121.2) 87.9 (33.7–122.0) 0.36
NRTIs
Zidovudine
Ever (%) 18 (69.2) 257 (68.9) 0.97
Exposurea 29.8 (0.0–62.8) 30.1 (0.0–76.8) 0.77
Didanosine
Ever (%) 13 (50.0) 179 (48.0) 0.84
Exposurea 3.2 (0.0–35.0) 0.0 (0.0–34.2) 0.81
Stavudine
Ever (%) 12 (46.1) 180 (48.3) 0.84
Exposurea 0.0 (0.0–43.5) 0.0 (0.0–0.0) 0.99
Tenofovir
Ever (%) 22 (84.6) 234 (62.7) 0.02
Exposurea 31.0 (21.1–56.6) 14.7 (0.0–38.3) 0.002
Abacavir
Ever (%) 11 (42.3) 143 (38.3) 0.69
Exposurea 0.0 (0.0–6.7) 0.0 (0.0–28.1) 0.25
NNRTIs
Efavirenz
Ever (%) 8 (30.8) 164 (44.0) 0.19
Exposurea 0.0 (0.0–14.5) 0.0 (0.0–19.4) 0.27
Nevirapine
Ever (%) 8 (30.8) 117 (31.4) 0.95
Exposurea 0.0 (0.0–21.9) 0.0 (0.0–6.5) 0.77
Protease inhibitors
Saquinavir
Ever (%) 5 (19.2) 66 (17.7) 0.84
Exposurea 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.92
Indinavir
Ever (%) 7 (26.9) 104 (27.9) 0.92
Exposurea 0.0 (0.0–1.1) 0.0 (0.0–4.4) 0.75
Lopinavir
Ever (%) 11 (42.3) 143 (38.3) 0.69
Exposurea 0.0 (0.0–25.5) 0.0 (0.0–17.7) 0.57
Atazanavir
Ever (%) 15 (57.7) 135 (36.2) 0.03
Exposurea 19.7 (0.0–41.4) 0.0 (0.0–14.2) 0.004
Ritonavir as a ‘booster’
Ever (%) 21 (80.8) 233 (62.5) 0.06
Exposurea 42.8 (14.3–58.1) 15.3 (0.0–50.7) 0.04
Abbreviations: HAART, highly active antiretroviral therapy; IQR, interquartile range;
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PRTD, proximal renal tubular dysfunction.
aData are n (%), or median (IQR) for cumulative treatment exposure, in months.
Bold values signify P-valueo0.05.
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tubules. Cardinal features are hyperaminoaciduria, glucosuria
in the face of normal serum glucose level, and phosphate
wasting. Other features can be associated, such as sodium,
water, potassium, bicarbonate, calcium, uric acid, or low-
molecular-weight protein wasting.20 In our study, five criteria
were selected to depict PRTD: glucosuria with normal
glycemia, hypophosphatemia with low ratio of the maximum
rate of renal tubular phosphate reabsorption to GFR (TmPi/
GFR), metabolic acidosis, hypouricemia with high fractional
excretion of uric acid, and proteinuria with high excretion of
b2-microglobulin. Meaningful PRTD was defined when two
or more of these parameters were present. Sodium, water,
potassium, and calcium wasting were excluded because these
features are not specific to PRTD. Metabolic acidosis was
included as a marker of bicarbonate wasting, because the
renal threshold for bicarbonate could not easily be assessed.
b2-microglobulin (molecular weight 11,800Da) was chosen
as an low-molecular-weight protein, as proposed by some
authors.21
The tubular dysfunctions analyzed in our study do not
represent all renal abnormalities. Most patients who pre-
sented with a GFR alteration or proteinuria had no PRTD.
Conversely, some patients with PRTD diagnosis were not
affected by GFR alteration or major proteinuria. Never-
theless, our results do not exclude the possibility of a long-
term impact of PRTD on glomerular function as most
anecdotal reports of acute or chronic renal failure associated
with antiretroviral drugs have been preceded or accompanied
by tubular abnormalities.22 Primary tubular abnormalities,
even severe, may be missed until they affect the glomerular
function; a specific and early screening is thus necessary to
prevent them. Another possible effect of renal tubular
dysfunction is bone demineralization disorders, which could
be mediated by increased renal phosphate loss, metabolic
acidosis or increased parathormone production.10,23
In this study, some factors found to be associated with
PRTD are not modifiable such as older age. Other factors,
however, can have therapeutic consequences. Our study
highlighted specific treatment effects, particularly the risk of
altered tubular fusnction, which was significantly associated
with an important cumulative exposure to TDF and/or
atazanavir. TDF is the first nucleotide analog licensed for
the treatment of HIV infection. Two other nucleoside
analogs, adefovir and cidofovir, are well-known nephrotoxic
agents.24,25 TDF is taken from the blood into the proximal
tubular cells and, after two additional phosphorylations, then
is extruded by the apical multidrug resistance protein
transporter into the tubular space, in which urine is
formed.26 In animal studies, high doses of TDF for prolonged
periods led to a Fanconi-like syndrome.27
In a retrospective review of the FDA’s Adverse Event
Reporting System, which collected data from 2001 to
2006, 164 subjects met the definition of Fanconi syndrome.
Table 3 | Factors associated with PRTD in HIV-infected patients: multivariate logistic regression analysis, Aquitaine cohort,
2008–2009 (n=399)
Full model Final model
Characteristics OR (95% CI) P-value OR (95% CI) P-value
Age (per additional 5 years) 1.28 (1.02–1.61) 0.03 1.28 (1.05–1.58) 0.017
Other antiviral drugsa 0.27 (0.07–0.95) 0.04
NSAID exposure 4.85 (0.40–58.56) 0.21
Lipodystrophy 1.80 (0.70–4.63) 0.22
HBV chronic hepatitis 1.84 (0.41–8.21) 0.42
Tenofovirb 1.16 (0.95–1.42) 0.15 1.23 (1.02–1.47) 0.028
Abacavirb 0.85 (0.68–1.07) 0.16
Atazanavirb 1.23 (0.96–1.58) 0.09 1.28 (1.04–1.58) 0.021
Ritonavir boosterb 1.03 (0.85–1.25) 0.76
Abbreviations: CI, confidence interval; HBV, hepatitis B virus; HIV, human immunodeficiency virus; NSAID, non-steroidal anti-inflammatory drugs; OR: odds ratio; PRTD,
proximal renal tubular dysfunction.
aAcyclovir, ganciclovir, adefovir, and cidofovir.
bRisk per additional year of exposure.
Table 4 | Factors associated with PRTD in HIV-infected
patients: multivariate logistic regression analysis according
to treatment exposure, Aquitaine cohort, 2008–2009
Final model
Characteristics OR (95% CI) P-value
Age (per additional 5 years) 1.34 (1.1–1.7) 0.01
Atazanavira
Never (ref) — — —
Stopped before inclusion
o4 yearsa 0.46 (0.1–3.8) 0.47
X4 yearsa 5.42 (0.5–62.4) 0.17
Ongoing
o4 yearsa 2.06 (0.6–6.6) 0.22
X4 yearsa 3.15 (1.1–8.9) 0.03
Tenofovira
Never (ref) — — —
Stopped before inclusion
o5 yearsa 2.90 (0.5–15.7) 0.22
X5 yearsa 11.49 (1.4–92.3) 0.02
Ongoing
o5 yearsa 3.52 (0.9–13.8) 0.07
X5 yearsa 5.22 (1.2–22.6) 0.03
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds
ratio; PRTD, proximal renal tubular dysfunction.
aCumulative treatment exposure.
Bold values signify P-valueo0.05.
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The majority (83%) of subjects received PIs in combination
with TDF; specifically, 74% received a ritonavir-boosted PI
(PI/r). Didanosine was the most commonly (43%) prescribed
NRTI and was frequently observed in PI/r regimens (34%). In
particular, use of didanosine plus lopinavir and ritonavir was
documented in 22% of the cases.28 Our study showed a
significant association between PRTD and TDF exposure in
univariable and multivariable analysis (OR¼ 1.23 per addi-
tional year of exposure, P¼ 0.028). Similarly, Horberg et al.14
found that TDF exposure in antiretroviral-naı¨ve patients was
associated with a significantly greater risk of developing
proximal tubular dysfunction, but their retrospective design
and sampling conditions restricted the tubular function
evaluation. Fux et al.12 conducted a cross-sectional survey
among 246 patients who had been treated with TDF for at
least 1 month, and reported a significant association between
TDF treatment and hypophosphatemia (P¼ 0.01). However,
most of the patients recruited were not fasting when
sampling for blood tests and phosphate loss was estimated
using the fractional excretion of phosphate, which may limit
tubular dysfunction detection.12 Our study did not measure
antiretroviral plasma concentrations but underlined a specific
effect of cumulative exposure to TDF. Rodriguez-Novoa
et al.29 examined prospectively the relationship between TDF
exposure and kidney tubular dysfunction in 92 HIV-infected
individuals. Median TDF plasma concentration was higher in
patients with tubular function impairment than in others.
These results suggest that higher TDF plasma levels may lead
to a greater accumulation of TDF in the renal tubular cells
and, consequently, to kidney toxicity. One should notice that,
as it has been reported for NRTIs, TDF requires intracellular
phosphorylation to exert its effect. Unfortunately, there are
few data describing the intracellular concentrations of TDF
diphosphate.30 The lack of variation of TDF concentrations
in plasma does not preclude pharmacokinetic and/or
pharmacodynamic interaction in tubular cells, leading to
enhanced renal toxicity.31 Moreover, relatively high intrain-
dividual variation on TDF clearance has been described by
some authors.32 Many factors could influence the risk of
developing tubular dysfunction including polymorphisms in
genes encoding drug transporters.33 Expert guidelines
recommend dose reduction in patients with renal impair-
ment for antiretrovirals that are primarily eliminated through
the kidneys, such as NRTIs and TDF. Guidelines also
emphasize that drugs should not be withheld for fear of
adverse events.34 The clinical utility of antiretroviral dose
adjustment to preserve renal function and minimize toxic
effects should be evaluated in further prospective investiga-
tions. In the present study, many patients were treated with
TDF, and the association between TDF exposure and
diagnosis of PRTD remained significant despite analysis
adjustment on infection duration and clinical stage. For
patients receiving TDF at the time of enrolment in the study,
a cumulative exposure period over 5 years was strongly
associated with the presence of PRTD (OR¼ 5.22, P¼ 0.03).
Besides, this association remained significant, regardless of
whether TDF use was ongoing or had been interrupted
before the inclusion. Furthermore, our findings are based on
longer exposure durations than previous reports.35 They
suggest a sustainable impact of TDF on tubular function
as the treatment is prolonged. It is noticeable that none of
the patients diagnosed with PRTD before evaluation were
substituted subsequently to a combination containing
didanosine, atazanavir, or TDF. Nevertheless, as the sample
size may have restricted the study power for this analysis,
which was not originally planned, further studies on large
sample are needed to examine the reversibility of these
disorders when TDF is discontinued.
We also found a significant association between the
detection of PRTD and atazanavir exposure in univariable
and multivariable analysis (OR¼ 1.28 per year of exposure,
P¼ 0.021). Cases of Fanconi syndrome have been reported in
patients treated concomitantly with TDF and either didano-
sine or PIs (such as lopinavir or atazanavir).28,36 A possible
explanation is the high plasma concentration of TDF when
the drug is coadministered with some PI/r.37 The mechanism
of TDF increase, however, has not been sufficiently
investigated so far. It could be the consequence of a modifi-
cation in the digestive absorption of TDF or could be due to
reduced TDF renal clearance among patients receiving a
PI/r.38,39 Labarga et al.11 reported a high proportion of
patients who experienced a tubular dysfunction when
receiving TDF-containing regimens, but in this study, the
use of PIs tended to be more common in patients receiving
TDF than others, resulting in a more difficult interpretation
of the respective effects of PI and TDF. Atazanavir was the
most frequently PI used in our study. Consequently, we
cannot exclude a class effect involving the boosted PI/r.
Some limitations in our cross-sectional design need to be
mentioned. Our study does not address the temporality of
the relationship between PRTD and associated factors.
Although a regression approach to adjust for confounding
variables does not provide an evidence for causal inference,
these results support the hypothesis that some factors could
mediate the occurrence of PRTD in HIV-infected patients.
We aimed to assess the clinical relevance of PRTD-associated
factors and their practical importance to propose a scheme to
be considered for routine care. Another technical limit is that
the renal function evaluation has not been widely validated in
HIV-infected populations. For example, estimated GFR has
not been validated against the gold standard of measured
GFR. Moreover, the one-time PRTD assessment must be
considered as a limitation and possibly leads to misclassifica-
tion. To date, the literature is sparse concerning intraindivi-
dual reproducibility of the assessment of tubular function,
including in the general population, highlighting the interest
of further dedicated studies. Lastly, although our cohort is
predominantly of Caucasian origin, there are no data that
would suggest that the prevalence of renal tubular disorders is
different according to other ethnic backgrounds.
The guidelines produced by the HIV Medicine Association
of the Infectious Diseases Society of America recommend
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that all patients should be assessed for existing kidney disease
with a screening for proteinuria and a calculated estimate of
renal function at the time of HIV diagnosis. Additionally, it is
recommended that patients with normal laboratory values
for renal function, but who are considered to be at high
risk for the development of proteinuric renal disease, should
undergo annual screening.34 Although no studies have
examined the utility of systematic screening for early kidney
disease in preventing the progression of renal dysfunction in
HIV-infected patients, there is evidence that early treatment
of chronic kidney disease is beneficial.34,40,41 In the present
study, we observed that PRTD was a frequent abnormality in
an unselected cohort of HIV-infected patients under routine
clinical management. Relying on estimated GFR alone should
not be proposed, as some patients may present with initial
isolated tubular dysfunction. Considering the elevated
prevalence of PRTD in our sample, specific studies should
be performed to evaluate the impact of a screening of tubular
function.
Despite these limitations, our findings have implications
for clinical and therapeutic care in HIV-infected patients. As
the frequencies of the different criteria used in the present
study were comparable, such screening could include a
simplified assessment of each of them (for example, blood
measurements of phosphorus, bicarbonate, creatinine, uric
acid, glucose, and concomitant urine tests for glucose,
proteins, albumin, and creatinine in fasting conditions).
In summary, PRTD was a frequent abnormality in this
French unselected cohort. Our patients were broadly exposed
to TDF (54.9% of the sample). The use of TDF and/or
atazanavir was associated with an increased risk of tubular
dysfunction. Longitudinal studies are needed to validate the
temporality and assess the impact of the long/chronic
exposure to TDF and PI, alone or in combination, on the
kidney function.
MATERIALS AND METHODS
Study population
A cross-sectional survey was carried out within the ANRS C03
Aquitaine cohort, a prospective hospital-based cohort of HIV-1-
infected patients under routine clinical management in southwestern
France.42 Inclusion criteria for this cohort were the following: adults
attending in- or outpatient services of the participating hospitals;
HIV-1 infection confirmed by western blot, regardless of clinical
stage; having attended to at least one follow-up contact after the first
clinic visit or having a known date of death; and having given an
informed consent. Standardized clinical, biological, and therapeutic
data collection was completed by attending physicians at the time
of enrolment and at each hospital follow-up visit, generally every 3 or
6 months or in case of any intercurrent event, then verified, and
coded by research nurses. The Bordeaux University Hospital Ethics
Committee approved the present study protocol.
Patients were eligible for the present study if they were still alive
and followed-up in April 2008. Written informed consent was
obtained from all participants. Discontinuation of phosphocalcic
supplementation, non-steroidal anti-inflammatory drug, or diure-
tics administration in the last 10 days and absence of vitamin D
supplementation within the previous 6 weeks were mandatory.
The following patient characteristics were recorded and extracted
from the cohort database: gender, age, HIV transmission group, HIV
diagnosis date and clinical stage according to the US Centers for
Disease Control and Prevention classification, hepatitis B and C
virus serological status, hypertension, diabetes, clinically defined
lipodystrophy, medication intake (including acetylsalicylic acid,
non-steroidal anti-inflammatory drug, cotrimoxazole prophylaxis,
pentamidine, amphotericin B, acyclovir, ganciclovir, adefovir, and
cidofovir treatment), and type and duration of specific antiretroviral
class exposure (including NRTI, non-nucleoside reverse transcrip-
tase inhibitor, and PI). A specific questionnaire was also completed
for each participant to document body mass index, alcohol and
tobacco consumption, history of previous kidney disease, myeloma,
autoimmune disease, and/or heavy metal exposure, as these
variables are known to be predictive factors of tubular dysfunction.
Kidney function assessment
Renal function tests were assessed by concomitant blood and urine
samples drawn in the morning after an overnight fast and after
a 30-min resting period. Blood variables included creatinine,
phosphorus, sodium, potassium, chlore, glucose, pH, bicarbonate,
and uric acid. Urine variables included creatinine, phosphorus,
uric acid, glucose, b2-microglobulin, albumin, and proteins. Urine
sterility was examined systematically with a cytobacteriological
culture.
The GFR was estimated using the simplified MDRD Study
Group equation.43 Proteinuria and albuminuria were defined as
urine protein/creatinine and albumin/creatinine ratios over
30mg/mmol and 3mg/mmol, respectively.44,45 The tubular metab-
olism of phosphates was assessed using TmPi/GFR, which provides
optimal evaluation of tubular reabsorption of phosphates.46
Hyperphosphaturia of tubular origin, sometimes also referred as
phosphate diabetes,47 was defined as a TmPi/GFR p0.77mmol/l,
with an hypophosphatemia o0.80mmol/l.
PRTD was defined on the basis of the presence of at least two
out of five of the following criteria:18 phosphate diabetes, non-
diabetic glucosuria (positive urine glucose with plasma glucose
o7.0mmol/l), metabolic acidosis (blood pHp7.34 and serum
bicarbonate p22mmol/l), ratio b2-microglobulinuria/urinary
creatinine 40.3mg/l, or low serum uric acid with uric acid
fractional excretion 415% (calculated as: (urine uric acid
plasma creatinine)/(urine creatinine plasma uric acid) 100).19
Laboratory methods
HIV plasma RNA was measured by real-time PCR using the COBAS
ampliPrep/Cobas Taqman HIV-1 Test (Roche Molecular Systems,
Branchburg, NJ), and CD4 cell counts were measured using flow
cytometry. Determination of urine b2-microglobulin was performed
using immunonephelometry. Other blood and urine analyses were
performed using the standard techniques in place at the Bordeaux
University Hospital central laboratory.
Statistical analysis
The prevalence of PRTD at the time of the study was estimated as the
number of PRTD events per 100 patients screened, and its 95% CI was
calculated by Poisson distribution. A multivariable analysis using
logistic regression evaluated factors associated with the presence
of PRTD. Variables with a P-value o0.25 in univariable analysis
were included in the full model. The final model was fitted using a
stepwise-descending procedure. Analyses were processed using STATA
software (version 9.2, Stata Corporation, College Station, TX).
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